Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII
Our findings indicate that FVIII can be safely used with emicizumab to counter the anticoagulant effect of DOAC at ≤100 ng/mL. The TG assay is an efficient tool to monitor plasma containing anti-FXa DOAC, but not dabigatran (anti-FIIa).
Authors
- Virginie Fourneyron
- Thomas Sinegre (ORCID: https://orcid.org/0000-0003-0945-1425)
- Sylvain Lamoine (ORCID: https://orcid.org/0000-0002-6216-8509)
- Laurie Talon (ORCID: https://orcid.org/0000-0003-0626-371X)
- Dorian Teissandier (ORCID: https://orcid.org/0000-0002-9698-3974)
- Aurélien Lebreton (ORCID: https://orcid.org/0000-0002-1650-0427)
- Vincent Jury
- Jonathan Douxfils
Institutions
- University of Namur (BE)
- Université Clermont Auvergne (FR)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1016/j.rpth.2024.102576
- Citations
- 2
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.91